Royal Bank of Canada
ABCL icon

Royal Bank of Canada’s AbCellera Biologics ABCL Stock Holding History

Royal Bank of Canada’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
394,753
+20,897
+6% +$75.2K ﹤0.01% 3378
2025
Q4 		$1.28M Sell
373,856
-130,108
-26% -$581K ﹤0.01% 3472
2025
Q3 		$2.54M Buy
503,964
+100,048
+25% +$441K ﹤0.01% 3202
2025
Q2 		$1.39M Buy
403,916
+16,885
+4% +$42K ﹤0.01% 3618
2025
Q1 		$863K Sell
387,031
-19,960
-5% -$57.2K ﹤0.01% 3592
2024
Q4 		$1.19M Sell
406,991
-393
-0.1% -$1.09K ﹤0.01% 3401
2024
Q3 		$1.06M Sell
407,384
-1,490
-0.4% -$4.13K ﹤0.01% 3502
2024
Q2 		$1.21M Buy
408,874
+16,517
+4% +$62.5K ﹤0.01% 3288
2024
Q1 		$1.78M Buy
392,357
+4,238
+1% +$21.6K ﹤0.01% 3015
2023
Q4 		$2.22M Sell
388,119
-6,483
-2% -$30K ﹤0.01% 2986
2023
Q3 		$1.81M Sell
394,602
-93,243
-19% -$567K ﹤0.01% 2927
2023
Q2 		$3.15M Sell
487,845
-663,416
-58% -$4.53M ﹤0.01% 2458
2023
Q1 		$8.68M Buy
1,151,261
+36,747
+3% +$334K ﹤0.01% 1658
2022
Q4 		$11.3M Buy
1,114,514
+26,041
+2% +$301K ﹤0.01% 1521
2022
Q3 		$10.8M Buy
1,088,473
+330,870
+44% +$3.63M ﹤0.01% 1478
2022
Q2 		$8.07M Sell
757,603
-69,690
-8% -$590K ﹤0.01% 1714
2022
Q1 		$8.07M Sell
827,293
-17,069
-2% -$162K ﹤0.01% 1880
2021
Q4 		$12.1M Buy
844,362
+657,862
+353% +$9.98M ﹤0.01% 1745
2021
Q3 		$3.74M Buy
186,500
+32,923
+21% +$582K ﹤0.01% 2551
2021
Q2 		$3.38M Buy
153,577
+86,785
+130% +$2.39M ﹤0.01% 2600
2021
Q1 		$2.27M Buy
66,792
+63,721
+2,075% +$2.54M ﹤0.01% 2904
2020
Q4 		$123K Buy
+3,071
New +$140K ﹤0.01% 5205

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada's ABCL Position: Q1 2026 in Review

Royal Bank of Canada increased its AbCellera Biologics (ABCL) stake by 5.6% in Q1 2026, buying an estimated $75.2K and bringing the position to 394,753 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3378.

Royal Bank of Canada first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $12.1M in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Royal Bank of Canada held 394,753 shares of AbCellera Biologics worth $1.38M as of Q1 2026.
  • Royal Bank of Canada bought 20,897 AbCellera Biologics shares in Q1 2026, an estimated $75.2K.
  • AbCellera Biologics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3378 holding.
  • Royal Bank of Canada first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's AbCellera Biologics position peaked at $12.1M in Q4 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.